PARP1 and neoplasm: However, in breast cancer (BRCA)-mutated BC, PARP inhibiting agents aid in tumor cell deaths through synthetic lethality (where the loss of two genes with similar function leads to cell death, while the loss of one of the genes has little or no lethal effect) in cells expressing HR deficiency (HRD) [34,62].